Publicação: 28 de outubro de 2019
TB Alliance Welcomes Global Drug Facility’s Listing of Pretomanid The Stop TB Partnership’s Global Drug Facility (GDF) has added the anti-TB drug pretomanid to its catalog of TB medicines. The “global access price” of US $364 for a six-month treatment course will be available to 150 countries representing the vast majority of the global TB […]
The Stop TB Partnership’s Global Drug Facility (GDF) has added the anti-TB drug pretomanid to its catalog of TB medicines. The “global access price” of US $364 for a six-month treatment course will be available to 150 countries representing the vast majority of the global TB burden.
“We applaud the GDF’s rapid response and view this listing as a significant milestone on the path to ensuring access for those in urgent need,” said Mel Spigelman, President and CEO, TB Alliance, which developed the new treatment option.
Learn more at TBAlliance.org
Non-profit drug developer TB Alliance has granted Macleods Pharmaceuticals Limited a non-exclusive license to manufacture the anti-TB drug pretomanid as part of the three-drug “BPaL” regimen.
Learn more at TBAlliance.org
Coming Up on Wednesday, October 30
14:30-16:00 | Avasa Hotel, Constellation Room
TB Alliance and partners will provide an update on treatment for highly drug-resistant forms of tuberculosis.
Featuring remarks from:
Panel discussion including:
We request that those interested in attending please RSVP to the event. Registration opens at 14:00 IST and the event will begin at 14:30, followed by a reception.
https://mailchi.mp/tballiance/tb-alliance-at-the-2019-union-conference-1140273?e=d36444e614